Bioactive lipids in schizophrenia

References

• Agranoff BW, Joyce AB, Hajra AK. Lipids. Basic neurochemistry: Molecular, cellular and medical aspects6th ed., GJ Siegel, BW Agranoff. Lippincott-Raven Publishers, Philadelphia 1998; 47–68
   Google Scholar
• Albers M, Meurer H, Marki F, Klotz J. Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients. Pharmacopsychiatry 1993; 26(3)94–98
   PubMedGoogle Scholar
• Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Molecular Neurobiology 2005; 32(1)89–103
   PubMed Web of Science ®Google Scholar
• Bazan NG, Packard MG, Teather L, Allan G. Bioactive lipids in excitatory neurotrans-mission and neuronal plasticity. Neurochemistry International 1997; 30(2)225–231
   PubMedGoogle Scholar
• Berger GE, Wood SJ, Pantelis C, Velakoulis D, Wellard RM, McGorry PD. Impli-cations of lipid biology for the pathogenesis of schizophrenia. Australia & New Zealand Journal of Psychiatry 2002; 36(3)355–366
   PubMed Web of Science ®Google Scholar
• Berger GE, Wood SJ, McGorry PD. Psychopharmacology Bulletin 2003; 37: 79–101
   PubMedGoogle Scholar
• Bluml S, Tan J, Harris K, Adatia N, Karme A, Sproull T, et al. Quantitative proton-decoupled 31P MRS of the schizophrenic brain in vivo. Journal of Computer Assisted Tomography 1999; 23(2)272–275
   PubMed Web of Science ®Google Scholar
• Brown AS, Susser ES, Butler PD, Richardson Andrews R, Kaufmann CA, Gorman JM. Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Journal of Nervous and Mental Disorders 1996; 184(2)71–85
   PubMedGoogle Scholar
• Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999; 29(3)697–701
   PubMed Web of Science ®Google Scholar
• Chowdari KV, Brandstaetter B, Semwal P, Bhatia T, Deshpande S, Reddy R, et al. Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples. Psychiatric Genetics 2001; 11(4)207–212
   PubMedGoogle Scholar
• Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatrica Scandinavica 1988; 78(5)587–591
   PubMed Web of Science ®Google Scholar
• Clifford JJ, Drago J, Natoli AL, Wong JY, Kinsella A, Waddington JL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002; 109(1)81–88
   PubMedGoogle Scholar
• Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition: The reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. Journal of Lipid Research 1990; 31(2)237–247
   PubMedGoogle Scholar
• Cunnane SC, Francescutti V, Brenna JT, Crawford MA. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 2000; 35(1)105–111
   PubMedGoogle Scholar
• Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Archives in General Psychiatry 2003; 60(5)443–456
   PubMed Web of Science ®Google Scholar
• Dean B, Laws SM, Hone E, Taddei K, Scarr E, Thomas EA, et al. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biological Psychiatry 2003; 54(6)616–622
   PubMedGoogle Scholar
• DeLisi LE. Is schizophrenia a lifetime disorder of brain plasticity, growth and aging?. Schizophrenia Research 1997; 23(2)119–129
   PubMedGoogle Scholar
• Devane WA, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proceedings of the National Academy of Sciences of the USA 1994; 91(14)6698–6701
   PubMedGoogle Scholar
• Doris A, Wahle K, MacDonald A, Morris S, Coffey I, Muir W, et al. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophrenia Research 1998; 31(2–3)185–196
   PubMedGoogle Scholar
• Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry 2002; 159(9)1596–1598
   PubMed Web of Science ®Google Scholar
• Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: Their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chemistry and Physics of Lipids 2000; 106(1)1–29
   PubMed Web of Science ®Google Scholar
• Farstad M. Determination of fatty acids in cerebrospinal fluid. V. The fatty acid content in the total lipids of cerebrospinal fluid in psychiatric patients. Scandinavian Journal of Clinical and Laboratory Investigations 1966; 18(3)343–346
   PubMed Web of Science ®Google Scholar
• Feinberg I. Cortical pruning and the development of schizophrenia. Schizophrenia Bulletin 1990; 16(4)567–570
   PubMedGoogle Scholar
• Feinberg I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?. Journal of Psychiatric Research 1982; 17(4)319–334
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry 2001; 158(12)2071–2074
   PubMedGoogle Scholar
• Fenton WS, Hibbeln J, Knable MB. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 2000; 47: 8–21
   PubMed Web of Science ®Google Scholar
• Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nature Cell Biology 2001; 3(11)E255–E263
   PubMed Web of Science ®Google Scholar
• Fiedler P, Wolkin A, Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biological Psychiatry 1986; 21(13)1347–1350
   PubMedGoogle Scholar
• Frieboes RM, Moises HW, Gattaz WF, Yang L, Li T, Liu X, et al. Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2. American Journal of Medical Genetics 2001; 105(3)246–249
   PubMedGoogle Scholar
• Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. American Journal of Psychiatry 1999a; 156(8)1205–1208
   PubMedGoogle Scholar
• Fukuzako H, Fukuzako T, Kodama S, Hashiguchi T, Takigawa M, Fujimoto T. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Neuropsychopharmacology 1999b; 21(4)542–549
   PubMedGoogle Scholar
• Gattaz WF, Brunner J. Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukotrienes and Essential Fatty Acids 1996; 55(1–2)109–113
   PubMedGoogle Scholar
• Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizo-phrenia. Schizophrenia Research 1995; 16(1)1–6
   PubMedGoogle Scholar
• Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: A replication study. Biological Psychiatry 1990; 28(6)495–501
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry 1987; 22(4)421–426
   PubMed Web of Science ®Google Scholar
• Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. British Journal of Psychiatry 2002; 181: 22–28
   PubMed Web of Science ®Google Scholar
• Glass M. The role of cannabinoids in neurodegenerative diseases. Progress in Neurology, Psychology and Biological Psychiatry 2001; 25(4)743–765
   PubMedGoogle Scholar
• Glen AI, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF. Mem-brane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukotrienes and Essential Fatty Acids 1996; 55(1–2)9–15
   PubMedGoogle Scholar
• Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N. A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophrenia Research 1994; 12(1)53–61
   PubMedGoogle Scholar
• Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences of the USA 2001; 98(8)4746–4751
   PubMed Web of Science ®Google Scholar
• Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lonnqvist J. Is low dietary intake of omega-3 fatty acids associated with depression?. American Journal of Psychiatry 2004; 161(3)567–569
   PubMed Web of Science ®Google Scholar
• Heleniak E, O’Desky I. Histamine and prostaglandins in schizophrenia: Revisited. Medical Hypotheses 1999; 52(1)37–42
   PubMedGoogle Scholar
• Henn FA. The biological concepts of schizophrenia. Perspectives in Schizophrenia Research, C Baxter, T Melnachuk. Raven Press, NewYork 1980; 209
   Google Scholar
• Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Molecular Psychiatry 2001; 6(1)66–73
   PubMed Web of Science ®Google Scholar
• Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351(9110)1213
   PubMed Web of Science ®Google Scholar
• Hitzemann R, Hirschowitz J, Garver D. Membrane abnormalities in the psychoses and affective disorders. Journal of Psychiatric Research 1984; 18(3)319–326
   PubMedGoogle Scholar
• Hoffer A. Adverse effects of niacin in emergent psychosis. Journal of the American Medical Association (JAMA) 1969; 207(7)1355
   PubMedGoogle Scholar
• Horrobin DF, Bennett CN. The membrane phospholipid concept of Schizophrenia. Search for the Causes of Schizophrenia. Balance of the Century, WF Gattaz, H Haefner. Springer, Darmstadt 1999; IV: 261–279
   Google Scholar
• Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurode-velopmental concept of schizophrenia. Schizophrenia Research 1998; 30(3)193–208
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukotrienes and Essential Fatty Acids 1996; 55(1–2)3–7
   PubMedGoogle Scholar
• Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 1991; 30(8)795–805
   PubMedGoogle Scholar
• Horrobin DF. Prostaglandins and schizophrenia. Lancet 1980; 1(8170)706–707
   PubMedGoogle Scholar
• Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1(8018)936–937
   PubMedGoogle Scholar
• Hudson CJ, Gotowiec A, Seeman M, Warsh J, Ross BM. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biological Psychiatry 1999; 46(3)401–405
   PubMedGoogle Scholar
• Hudson CJ, Lin A, Cogan S, Cashman F, Warsh JJ. The niacin challenge test: Clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biological Psychiatry 1997; 41(5)507–513
   PubMedGoogle Scholar
• Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, et al. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophrenia Research 1996; 21(2)111–116
   PubMedGoogle Scholar
• Innis SM, Sprecher H, Hachey D, Edmond J, Anderson RE. Neonatal polyunsaturated fatty acid metabolism. Lipids 1999; 34(2)139–149
   PubMed Web of Science ®Google Scholar
• Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability. European Archives in Psychiatry & Clinical Neuroscience 2000; 250(6)274–285
   PubMed Web of Science ®Google Scholar
• Junqueira R, Cordeiro Q, Meira-Lima I, Gattaz WF, Vallada H. Allelic association analysis of phospholipase A2 genes with schizophrenia. Psychiatric Genetics 2004; 14(3)157–160
   PubMedGoogle Scholar
• Kegeles LS, Humaran TJ, Mann JJ. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biological Psychiatry 1998; 44(6)382–398
   PubMedGoogle Scholar
• Keshavan MS, Stanley JA, Montrose DM, Minshew NJ, Pettegrew JW. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: An in vivo 31P MRS study. Molecular Psychiatry 2003; 8: 316–323
   PubMedGoogle Scholar
• Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-part II. Biological Psychiatry 2000; 48(5)369–380
   PubMedGoogle Scholar
• Keshavan MS, Montrose DM, Pierri JN, Dick EL, Rosenberg D, Talagala L, et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: Preliminary studies. Progess in Neuropsychopharmacology & Biological Psychiatry 1997; 21(8)1285–1295
   PubMedGoogle Scholar
• Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. Journal of Psychiatric Research 1994; 28(3)239–265
   PubMedGoogle Scholar
• Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. Erythrocyte membrane phos-pholipids in psychotic patients. Psychiatry Research 1993; 49(1)89–95
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Pettegrew JW, Panchalingam KS, Kaplan D, Bozik E. Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. Archives in General Psychiatry 1991; 48(12)1112–1113
   PubMedGoogle Scholar
• Lautin A, Cordasco DM, Segarnick DJ, Wood L, Mason MF, Wolkin A, et al. Red cell phospholipids in schizophrenia. Life Sciences 1982; 31(26)3051–3056
   PubMedGoogle Scholar
• Leask S, Done DJ, Crow TJ, Richards M, Jones P. No association between breast-feeding and adult psychosis in two national birth cohorts. British Journal of Psychiatry 2000; 177: 218–221
   PubMed Web of Science ®Google Scholar
• Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Archives in General Psychiatry 2001; 58(6)573–578
   PubMedGoogle Scholar
• Lonergan PE, Martin DS, Horrobin DF, Lynch MA. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. Journal of Biology & Chemistry 2002; 277(23)20804–20811
   PubMedGoogle Scholar
• Mahadik SP, Khan MM, Evans DR, Parikh VV. Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophrenia Research 2002; 58(1)55–62
   PubMedGoogle Scholar
• Mahadik SP, Mulchandoni M, Mahabaleshwar HV, Ranjekar PK. Cultural and socio-economic differences in dietary intake of essential fatty acids and antioxidants: Effects on the course and outcome of schizophrenia. Phospholipid Spectrum Disorder in Psychiatry, M Peet, I Glen, D Horrobin. Marius Press, Carnforth, UK 1999; 167–179
   Google Scholar
• Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biological Psychiatry 1998; 43(9)674–679
   PubMedGoogle Scholar
• McCreadie RG. The Nithsdale Schizophrenia Surveys. 16. Breast-feeding and schizophrenia: Preliminary results and hypotheses. British Journal of Psychiatry 1997; 170: 334–337
   PubMed Web of Science ®Google Scholar
• Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Human Psychopharmacology 1996; 11: 39–46
   Web of Science ®Google Scholar
• Mellsop GW. Schizophrenia and rheumatoid arthritis. Australia & New Zealand Journal of Psychiatry 1972; 6(4)214
   PubMed Web of Science ®Google Scholar
• Messamore E, Hoffman WF, Janowsky A. The niacin skin flush abnormality in schizophrenia: A quantitative dose-response study. Schizophrenia Research 2003; 62(3)251–258
   PubMed Web of Science ®Google Scholar
• Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signalling 4 (RGS4) expression in schizophrenia. Molecular Psychiatry 2001; 6(3)293–301
   PubMed Web of Science ®Google Scholar
• Morgan J, Capuzzi D, Guyton J. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. American Journal of Cardiology 1998; 82(12A)29U–34U, discussion 39U–41U
   Google Scholar
• Morrow JD, Awad JA, Oates JA, Roberts IInd LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. Journal of Investigative Dermatology 1992; 98(5)812–815
   PubMedGoogle Scholar
• Mrazek PJ, Haggerty RJ. New directions in definition. Reducing Risks for Mental Disorders. Frontiers for preventive Intervention Research, PJ Mrazek, RJ Haggerty. National Academy Press, Washington, DC 1994; 19–29
   Google Scholar
• Muller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Moller HJ, et al. COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. European Archives in Psychiatry & Clinical Neuroscience 2004; 254(1)14–22
   PubMed Web of Science ®Google Scholar
• Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 2002; 159(3)477–479
   PubMed Web of Science ®Google Scholar
• Ness AR, Gallacher JE, Bennett PD, Gunnell DJ, Rogers PJ, Kessler D, et al. Advice to eat fish and mood: A randomised controlled trial in men with angina. Nutrition & Neuroscience 2003; 6(1)63–65
   PubMed Web of Science ®Google Scholar
• Nichols PD, Virtue P, Mooney BP, Elliot NG, Yearsley GK. Seafood the good Food. The oil (fat) content and composition of Australian commercial fishes, shellfishes and crustaceans. Marine Research 1998
   Google Scholar
• Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biological Psychiatry 1993; 34(9)641–649
   PubMedGoogle Scholar
• Oken RJ, Schulzer M. At issue: Schizophrenia and rheumatoid arthritis. The negative association revisited. Schizophrenia Bulletin 1999; 25(4)625–638
   PubMedGoogle Scholar
• Pae CU, Yu HS, Lee KU, Kim JJ, Lee CU, Lee SJ, et al. BanI polymorphism of the cytosolic phospholipase A2 gene may confer susceptibility to the development of schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2004; 28(4)739–741
   PubMedGoogle Scholar
• Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives in General Psychiatry 2002; 59(10)913–919
   PubMed Web of Science ®Google Scholar
• Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 2001; 49(3)243–251
   PubMed Web of Science ®Google Scholar
• Peet M, Poole J, Laugharne J. Breastfeeding, neurodevelopment, and schizophrenia. Phospholipid Spectrum Disorder in Psychiatry, M Peet, I Glen, D Horrobin. Marius Press, Carnforth, UK 1999; 159–166
   Google Scholar
• Peet M, Ramchand CN, Lee J, Telang SD, Vankar GK, Shah S, et al. Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia. Psychiatric Genetics 1998; 8(3)191–192
   PubMedGoogle Scholar
• Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in eryth-rocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids 1996; 55(1–2)71–75
   PubMedGoogle Scholar
• Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Archives in General Psychiatry 1991; 48(6)563–568
   PubMedGoogle Scholar
• Phillips M, Erickson GA, Sabas M, Smith JP, Greenberg J. Volatile organic compounds in the breath of patients with schizophrenia. Journal of Clinical Pathology 1995; 48(5)466–469
   PubMed Web of Science ®Google Scholar
• Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 1991; 353(6340)164–167
   PubMedGoogle Scholar
• Potwarka JJ, Drost DJ, Williamson PC, Carr T, Canaran G, Rylett WJ, et al. A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biological Psychiatry 1999; 45(6)687–693
   PubMedGoogle Scholar
• Price SA, Fox H, St Clair D, Shaw DJ. Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene. Psychiatric Genetics 1997; 7(3)111–114
   PubMedGoogle Scholar
• Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology 2005; 65(2)286–292
   PubMed Web of Science ®Google Scholar
• Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. NeuroReport 2002a; 13(1)123–126
   PubMedGoogle Scholar
• Puri BK, Counsell SJ, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatment-resistant depression. Archives in General Psychiatry 2002b; 59(1)91–92
   PubMedGoogle Scholar
• Ramchand CN, Wei J, Lee KH, Peet M. Phospholipase A2 Gene Polymorphism and associated Biochemical Alterations in Schizophrenia. Phospholipid Spectrum Disorder in Psychiatry, M Peet, I Glen, D Horrobin. Marius Press, Carnforth, UK 1999; 31–39
   Google Scholar
• Richardson AJ, Montgomery P. The Oxford-Durham study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005; 115(5)1360–1366
   PubMed Web of Science ®Google Scholar
• Ripova D, Strunecka A, Nemcova V, Farska I. Phospholipids and calcium alterations in platelets of schizophrenic patients. Physiological Research 1997; 46(1)59–68
   PubMedGoogle Scholar
• Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Research 1999; 821(2)407–413
   PubMedGoogle Scholar
• Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2 [see comments]. Archives in General Psychiatry 1997; 54(5)487–494
   PubMed Web of Science ®Google Scholar
• Rotrosen J, Wolkin A. Phopholipid and prostaglandin hypotheses of schizophrenia. Psychopharmacology. The Third Generation of Progress, H Meltzer. Raven Press, New York 1987; 759–764
   Google Scholar
• Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: Substrate pellagra. Biological Psychiatry 1981; 16(9)837–850
   PubMedGoogle Scholar
• Rybakowski J, Weterle R. Niacin test in schizophrenia and affective illness. Biological Psychiatry 1991; 29(8)834–836
   PubMed Web of Science ®Google Scholar
• Sasaki T, Okazaki Y, Akaho R, Masui K, Harada S, Lee I, et al. Type of feeding during infancy and later development of schizophrenia. Schizophrenia Research 2000; 42(1)79–82
   PubMedGoogle Scholar
• Schachter H, Kourad K, Merali Z, Lumb A, Tran K, Miguelez M, et al. Effects of omega-3 fatty acids on mental health. (No. 116). 2005, Rockville, MD: Prepared by University of Ottawa Evidence-based Practice Center, Under Contract No. 290-02-0021
   Google Scholar
• Schurhoff F, Krebs MO, Szoke A, Loze JY, Goldberger C, Quignon V, et al. Apolipoprotein E in schizophrenia: A French association study and meta-analysis. American Journal of Medical Genetics 2003; 119B(1)18–23
   PubMedGoogle Scholar
• Shah SH, Vankar GK, Peet M, Ramchand CN. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin [letter]. Schizophrenia Research 2000; 43(2–3)163–164
   PubMedGoogle Scholar
• Shah SH, Vankar GK, Telang SD, Ramchchand CN, Peet M. Eicosapentanoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophrenia Research 1998; 29: 158
   Web of Science ®Google Scholar
• Sinclair AJ, Murphy KJ, Li D. Marine lipids: Overview ‘news insights and lipid composi-tion of Lyprinol’. Allergies & Immunology (Paris) 2000; 32(7)261–271
   PubMedGoogle Scholar
• Six DA, Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: Classification and characterization. Biochimica Biophysica Acta 2000; 1488(1–2)1–19
   PubMed Web of Science ®Google Scholar
• Smesny S, Kinder D, Willhardt I, Rosburg T, Lasch J, Berger G, et al. Increased calcium-independent phospholipase A2 activity in first but not in multi-episode chronic schizophrenia. Biological Psychiatry 2005; 57(4)399–405
   PubMed Web of Science ®Google Scholar
• Smesny S, Berger G, Rosburg T, Riemann S, Riehemann S, McGorry P, et al. Potential use of the topical niacin skin test in early psychosis—a combined approach using optical reflection spectroscopy and a descriptive rating scale. Journal of Psychiatric Research 2003; 37(3)237–247
   PubMedGoogle Scholar
• Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy [published erratum appears in Archives of General Psychiatry 1995 Oct; 52 (10) : 799] [see comments]. Archives of General Psychiatry 1995; 52(5)399–406
   PubMedGoogle Scholar
• Stevens JD. The distribution of the phospholipid fractions in the red cell membrane of schizophrenics. Schizophrenia Bulletin 1972; 6: 60–61
   Google Scholar
• Stoll AL. Fish consumption, depression, and suicidality in a general population. Archives of General Psychiatry 2001; 58(5)512–513
   PubMedGoogle Scholar
• Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial [see comments]. Archives of General Psychiatry 1999; 56(5)407–412
   PubMed Web of Science ®Google Scholar
• Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Journal of Neuropsychopharmacology 2003; 13(4)267–271
   PubMed Web of Science ®Google Scholar
• Sutcliffe JG, Thomas EA. The neurobiology of apolipoproteins in psychiatric disorders. Molecular Neurobiology 2002; 26(2–3)369–388
   PubMedGoogle Scholar
• Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, Sasaki S, et al. Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. British Journal of Cancer 2004; 90(4)787–793
   PubMedGoogle Scholar
• Tao R, Yu Y, Zhang X, Guo Y, Shi J, Xie L, et al. Cytosolic PLA2 genes possibly contribute to the etiology of schizophrenia. American Journal of Medical Genetics & Neuropsychiatric Genetics 2005; 137(1)56–58
   Google Scholar
• Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophrenia Research 2003; 61(1)1–6
   PubMed Web of Science ®Google Scholar
• Thomas EA, Dean B, Scarr E, Copolov D, Sutcliffe JG. Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder. Molecular Psychiatry 2003; 8(2)167–175
   PubMedGoogle Scholar
• Thomas EA, Danielson PE, Nelson PA, Pribyl TM, Hilbush BS, Hasel KW, et al. Clozapine increases apolipoprotein D expression in rodent brain: Towards a mechanism of neuroeptic pharmacotherapy. Journal of Neurochemistry 2001a; 76: 789–796
   PubMed Web of Science ®Google Scholar
• Thomas EA, Dean B, Pavey G, Sutcliffe JG. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: Implications for the pathophysiology of psychiatric disorders. Proceedings of the National Academy of Sciences of the USA 2001b; 98(7)4066–4071
   PubMedGoogle Scholar
• Torres IC, Mira L, Ornelas CP, Melim A. Study of the effects of dietary fish intake on serum lipids and lipoproteins in two populations with different dietary habits. British Journal of Nutrition 2000; 83(4)371–379
   PubMedGoogle Scholar
• Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. NeuroReport 2002; 13(1)29–33
   PubMed Web of Science ®Google Scholar
• Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research 1989; 27(3)313–323
   PubMedGoogle Scholar
• Vaddadi KS, Gilleard C, Mindham R, Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology (Berlin) 1986; 88(3)362–367
   PubMedGoogle Scholar
• Vance AL, Velakoulis D, Maruff P, Wood SJ, Desmond P, Pantelis C. Magnetic resonance spectroscopy and schizophrenia: What have we learnt?. Australia & New Zealand Journal of Psychiatry 2000; 34(1)14–25
   PubMed Web of Science ®Google Scholar
• Waldo MC, Freedman R. Neurobiological abnormalities in the relatives of schizophrenics. Schizophrenia Research 1999; 33(6)491–495
   Google Scholar
• Ward PE, Sutherland J, Glen EM, Glen AI. Niacin skin flush in schizophrenia: A preliminary report. Schizophrenia Research 1998; 29(3)269–274
   PubMedGoogle Scholar
• Wei J, Hemmings GP. A study of a genetic association between the PTGS2/PLA2G4A locus and schizophrenia. Prostaglandins Leukotrienes and Essential Fatty Acids 2004; 70(4)413–415
   PubMedGoogle Scholar
• Wei J, Lee KH, Hemmings GP. Is the cPLA2 gene associated with schizophrenia?. Molecular Psychiatry 1998; 3(6)480–481
   PubMedGoogle Scholar
• Wilson DW, Douglass AB. Niacin skin flush is not diagnostic of schizophrenia. Biological Psychiatry 1986; 21(10)974–977
   PubMedGoogle Scholar
• Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. American Journal of Psychiatry 1986; 143(7)912–914
   PubMedGoogle Scholar
• Yao JK, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biological Psychiatry 2002; 52(8)823–830
   PubMedGoogle Scholar
• Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophrenia Research 2000a; 42(1)7–17
   PubMed Web of Science ®Google Scholar
• Yao JK, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW. Correlation between RBC fatty acids and 31P MRS brain measures in schizophrenia. Society for Biological Psychiatry 2000b; 47: 41
   Web of Science ®Google Scholar
• Yao JK, van Kammen DP, Gurklis JA. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Research 1996; 60(1)11–21
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophrenia Research 1994a; 11(3)209–216
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research 1994b; 13(3)217–226
   PubMedGoogle Scholar
• Yu YQ, Tao R, Wei J, Xu Q, Liu SZ, Ju GZ, et al. No association between the PTGS2/PLA2G4A locus and schizophrenia in a Chinese population. Prostaglandins Leukotrienes and Essential Fatty Acids 2004; 71(6)405–408
   PubMedGoogle Scholar
• Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry 2003; 160(1)167–169
   PubMed Web of Science ®Google Scholar